Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma

Table 3

Main characteristics and results obtained in the studies with paclitaxel in patients with advanced angiosarcoma.

Author, year [ref]	Type of study	Paclitaxel dose and schedule	Period of treatment	Number of patients	Response rate (%)	PFS; (median)	OS; (median)
Fata et al., 1999 [20]	Retrospective	250 mg/m^2 continuous infusion for 24 h every 3 weeks or 175 mg/m^2 every 3 weeks or 90 mg/m^2 weekly	1992–1998	9	89	TTP 5 months	n.a.
Schlemmer et al., 2008 [21]	Retrospective	135–175 mg/m^2 every 3 weeks () or 75–100 mg/m^2 weekly ()	1996–2005	32	62	TTP 7.6 months	n.a.
Penel et al., 2008 [22]	Prospective	80 mg/m^2 on days 1, 8, and 15, every 4 weeks	2005–2006	30 (assessable 27)	18-19	TTP 4 months	8 months
Penel et al., 2012 [9]	Retrospective	Weekly schedule	1996–2009	47	45	TTP 5.6 months	13.1 months
Italiano et al., 2012 [23]	Retrospective	80 mg/m^2 on days 1, 8, and 15, every 4 weeks	1990–2010	75	53	5.8 months	10.3 months
Ray-Coquard et al., 2015 [24]	Prospective	Control arm: paclitaxel 90 mg/m^2 on days 1, 8, and 15, every 4 weeks, for 6 cycles	2010–2013	26		PFS: 6.8 mo; Progression-free rate at 6 months: 57%	Overall survival at 1 year: 55%
		Experimental arm: same as control arm + bevacizumab 10 mg/kg on days 1, 8, and 15 followed by maintenance therapy 15 mg/kg/3 wks until intolerance/progression	2010–2013	26		PFS: 6.9 mo; Progression-free rate at 6 months: 57%	Overall survival at 1 year: 58%
Our study	Prospective + retrospective	80 mg/m^2 on days 1, 8, and 15, every 4 weeks	Prospective: 2002–2006; Retrospective: 2003–2011	18 (17 evaluable)	35	4.6 months	18.6 months

PFS: progression-free survival; OS: overall survival; TTP: time-to-progression; n.a.: not available.